The FDA has given accelerated approval to Bayer for oral HER2 tyrosine kinase inhibitor sevabertinib as a second-line treatment for advanced HER2-mutant non-small cell lung cancer (NSCLC), allowing it ...

A retired grandad, who regularly cycled about 90 miles a week, says a routine health check may have saved his life after it ...

NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ ...

Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy Underscores IMDELLTRA as a Recognized Standard ...

Researchers advance mRNA cancer therapies as France tests new methods, while the FDA approves Bayer’s Hyrnuo for HER2-mutated ...

The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...

1. Food and Drug Administration. FDA grants traditional approval to tarlatamab-dlle for extensive-stage small-cell lung cancer. FDA. November 19, 2025. Accessed November 19, 2025.

The FDA has granted approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced or metastatic, ...

Joanne Cure, 78, survived stage 4 lung cancer after being given two years to live, crediting her faith, determination, and ...

Nuvalent filed a new drug application for an experimental non-small cell lung cancer treatment with the Food and Drug Administration.

Amgen's Imdelltra received full approval from the Food and Drug Administration for use in patients with lung cancer. The biotechnology company said Wednesday Imdelltra received approval for adult ...